

SUPPLEMENTAL AMENDMENT

Please amend the above referenced application as follows:

**In the Claims**

Please cancel claim 24 without prejudice, amend claims 20, 21, and 25, and add new independent claim 26 as set forth below:

**AMENDED CLAIM 20**

*G1*  
--20. (Amended) The antibody of Claim 19, wherein the antibody is [being] administered in association with an extracorporeal circulation procedure.--

**AMENDED CLAIM 21**

*M K17*  
--21. (Amended) A sterile non-pyrogenic therapeutic agent [for use in association with extracorporeal circulation procedures, wherein the therapeutic agent is sterile and non-pyrogenic and comprises] comprising the antibody of Claim 1 and a pharmaceutically effective carrier.--

**AMENDED CLAIM 25**

*G2*  
--25. (Amended) The therapeutic agent of Claim [24] 21 wherein the antibody is [a humanized antibody] made up of two or more heterodimeric subunits each containing one heavy and one light chain.--

**NEW CLAIM 26**

*G3*  
--26. Antibody 5G1.1 scFv CB (humanized) having the amino acid sequence encoded by the nucleic acid sequence of SEQ ID NO:8.

**Remarks**

This is supplemental to the supplemental amendments of January 11, 1999, November 4, 1998, and the response, mailed August 14, 1998, to the Office Action dated February 18, 1998 in the above referenced application. No extension of time is believed to be required for this paper, but should any such extension be required the Commissioner is requested to consider this a petition therefor. The Commissioner is

198